• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Immunity After Childhood Vaccinations in Perinatally HIV-exposed Children With and Without HIV Infection in Latin America

Thumbnail
Date
2018
Author
Succi, Regina Célia de Menezes [UNIFESP]
Krauss, Margot R.
Harris, D. Robert
Machado, Daisy Maria [UNIFESP]
Moraes-Pinto, Maria Isabel de [UNIFESP]
Mussi-Pinhata, Marisa M.
Ruz, Noris Pavia
Pierre, Russell B.
Roca, Lenka A. Kolevic
Joao, Esau
Foradori, Irene
Scotta, Marcelo C.
Hazra, Rohan
Siberry, George K.
Type
Artigo
ISSN
0891-3668
Is part of
Pediatric Infectious Disease Journal
DOI
10.1097/INF.0000000000001831
Metadata
Show full item record
Abstract
Background: Perinatally HIV-infected (PHIV) children are at risk for under-vaccination and poor vaccine response at 4 years of age. Childhood vaccine coverage and immune response were compared between PHIV and HIV-exposed uninfected (HEU) children in Latin America and the Caribbean. Methods: PHIV and HEU children were enrolled prospectively at 15 sites from 2002 to 2009. Full vaccination by age 4 years was defined as: 3 hepatitis B virus vaccine doses
 
4 tetanus toxoid-containing vaccine doses
 
3 doses of Haemophilus influenzae type b vaccine by age 12 months or >= 1 dose given after age 12 months
 
one measles-containing vaccine dose
 
one rubella-containing vaccine dose. Immunity was defined by serum antibody titer. Fisher exact test (for categorical measures) and t test (for continuous measures) were used for comparisons. Results: Among 519 children seen at age 4 years, 191 had serum specimens available (137 PHIV, 54 HEU). Among those with specimens available, 29.3% initiated combination antiretroviral therapy (cART) <12 months of age, 30.9% initiated at >= 12 months of age, and 39.8% had not received cART by the time they were seen at 4 years of age. At 4 years of age, 59.9% were on PI-containing cART (cART/PI), and 20.4% were on no ART. PHIV children were less likely than HEU children to be fully vaccinated for tetanus (55.5% vs. 77.8%, P = 0.005) and measles and rubella (both 70.1% vs. 94.4%, P < 0.001). Among those fully vaccinated, immunity was significantly lower among PHIV than HEU for all vaccines examined: 20.9% versus 37.8% for hepatitis B virus (P = 0.04), 72.0% versus 90.5% for tetanus (P = 0.02), 51.4% versus 68.8% for H. influenzae type b (P = 0.05), 80.2% versus 100% for measles (P < 0.001) and 72.9% versus 98.0% for rubella (P < 0.001) vaccine, respectively. Conclusions: Compared with HEU, PHIV children were significantly less likely to be immune to vaccine-preventable diseases when fully vaccinated. Strategies to increase immunity against vaccine-preventable diseases among PHIV require further study.
 
Citation
Pediatric Infectious Disease Journal. Philadelphia, v. 37, n. 4, p. 304-309, 2018.
Keywords
pediatric HIV infection
vaccination
immunity
Latin America
Sponsorship
NICHD
URI
https://repositorio.unifesp.br/handle/11600/55672
Collections
  • EPM - Artigos [17701]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV